AzTrials
AzTrials

Prosthetic Joint InfectionNCT03714165

Alpha Defensin and 16S rRNA Gene in Diagnosis of PJI

An observational study of Prosthetic Joint Infection, run by Assiut University at 1 site in Egypt.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Total joint replacement is considered one of the most successful surgical procedures in the field of orthopedics. Despite this achievement, prosthetic joint infections is still considered a severe complication often leading to catastrophic results and requiring repeated and extensive treatment. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
Conditions the study is for
Prosthetic Joint Infection
What is being tested?
Alpha defensin and 16SrRNA gene
How many people
90 participants
Where
1 siteEgypt
Study dates
1 Jan 2019to 1 Jan 2020
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: This study will be conducted on 90 informed individuals (according to guidelines of ethical committee of faculty of medicine , Assuit University )

Who may be able to join

  • The study will include all patient with prosthetic joint suspected to be infected through clinical manifestation (fever, pain, fistula redness, swelling ,hotness and loss of function) associated with radiological evidence.

Who cannot join

  • Any patient began antibiotic treatment will be excludes from the samples.

Trial locations and contacts

1 site in 1 country.

Ayat Bakhet Mostafa, Dr contact

01003880813

ayabakhet87@yahoo.com

Egypt1 site, 1 recruiting
  • Ayat Bakhet Mostafa

    Asyut

    Ayat Bakhet Mostafa, Dr, 01003880813, ayabakhet87@yahoo.com

    Recruiting

Other trials in Egypt

About this study

Official title: Utility of Alpha Defensin and 16S rRNA Gene in Diagnosis of Prosthetic Joint Infection

Total joint replacement is considered one of the most successful surgical procedures in the field of orthopedics. Despite this achievement, prosthetic joint infections is still considered a severe complication often leading to catastrophic results and requiring repeated and extensive treatment.

The incidence of PJI (a prosthetic joint infection) varies depending on the joint involved; the rate of arthroplasties becoming infected is as follows: 1.7% of primary and 3.2%of non-primary hip arthroplasties.

Read more

The accurate diagnosis of prosthetic joint infection often involves the combination of multiple factors including symptoms, signs, synovial fluid cell count, serum inflammatory markers, and culture.

The sensitivity of synovial fluid culture is only 85%, so a negative culture does not rule out infection. However, the specificity of synovial fluid culture is approximately 95%, and positive cultures often imply the presence of prosthetic joint infection.

The synovial fluid alpha-defensin test is an immunoassay that was specifically developed to aid in the diagnosis of prosthetic joint infection .

The sensitivity and the specificity of the alpha-defensin immunoassay test have been reported to be above 96%.

Molecular diagnostic tests using polymerase chain reaction (PCR) are emerging as a tool for the diagnosis of infections and noninfectious conditions. The application of PCR techniques with primers derived from the highly conserved regions of the bacterial 16S rRNA gene has been useful in the detection of bacterial organisms.

Use of broad-range 16S rRNA gene PCR as a tool for identification of bacteria is possible because the 16S rRNA gene is present in all bacteria .

Aim of the work:

.Determine sensitivity and specificity of alpha defensing and 16S rRNA gene in diagnosis of prosthetic joint infection.

  • Detection of antibiotic sensitivity for different organisms isolated from synovial fluid
Read the detailed description

Total joint replacement is considered one of the most successful surgical procedures in the field of orthopedics, alleviating pain and limitation of movement due to degenerative or traumatic joint damage. Despite this achievement, prosthetic joint infections is still considered a severe complication often leading to catastrophic results and requiring repeated and extensive treatment .

Infection is a major problem in orthopedics leading to implant failure. It is a challenging task to treat orthopedic implant infections that may lead to implant replacement and, in severe cases, may result in amputation and mortality Sources of infectious bacteria include the environment of the operating room, surgical equipment, clothing worn by medical and paramedical staff, resident bacteria on the patient's skin and bacteria already residing in the patient's body Implant-associated infections are the result of bacteria adhesion to an implant surface and subsequent biofilm formation at the implantation site .

Staphylococci account for more than 50% of total prosthetic joint infections. Approximately 20% may be polymicrobial, 15% caused by gram-negative, and about 10% are culture negative .

The incidence of PJI (a prosthetic joint infection) varies depending on the joint involved; the rate of arthroplasties becoming infected is as follows: 1.7% of primary and3.2%of non-primary hip arthroplasties .

A correct and early appropriate therapy if correct and timely microbiological diagnosis of infections is done within 4 weeks, it could be possible to follow a conservative approach on the prosthesis, since microorganisms are not yet organized in biofilms. A delayed diagnosis (>4 weeks) of early and late infections involves the necessity of prosthesis removal due to the production of a structured and mature microbial biofilm . The definition of PJI was recently revised by the International Consensus Group on Periprosthetic Joint Infection

According to PJI Consensus Group, patients should be considered to have a PJI if they meet one of the major criteria or at least three of the minor criteria:

Major criteria are as follows:

  1. Two positive periprosthetic cultures with phenotypically identical organisms.
  2. A sinus tract communicating with the joint.

Minor criteria are as follows:

  1. Elevated serum C reactive protein and erythrocyte sedimentation rate.
  2. Elevated synovial fluid white blood cell (WBC) count or ++ change on leukocyte esterase test strip.
  3. Elevated synovial fluid polymorph nuclear neutrophil percentage.
  4. positive histological analysis of periprosthetic tissue.
  5. A single positive culture .

Risk factors:

Different pathologies can increase the risk of prosthesis infections: previous infections, obesity, diabetes mellitus, immunodeficiency, and malnutrition or drugs therapy. The clinical assessment provides more details for the suspicion of infection. During physical examination, the surgeon can find the typical inflammation signs as swelling, redness, pain and loss of function .

the most frequent sign was loss of function (95%), followed by pain (85%) and swelling furthermore only 22% of patients presented fever and 14% had feeling of illness but 19% had fistula as primary sign of infection .

Diagnosis:

The accurate diagnosis of prosthetic joint infection often involves the combination of multiple factors including symptoms, signs, synovial fluid cell count, serum inflammatory markers, and culture .

A culture is an important tool for the diagnosis of prosthetic joint infection. Aspirated joint fluid culture should be sent in multiple sets of culture media.

The sensitivity of synovial fluid culture is only 85%, so a negative culture does not rule out infection. However, the specificity of synovial fluid culture is approximately 95%, and positive cultures often imply the presence of prosthetic joint infection .

Numerous preoperative tests for determination and diagnosis of a failed total hip replacement are available. These tests include hematological screening tests (measurement of the erythrocyte sedimentation rate, and the level of C-reactive protein, white blood-cell count,), aspiration of the hip joint, plain radiography, and radionuclide imaging studies. None of these tests is 100 % reliable and are subject to a variable spectrum of false negative or false positive results. A misdiagnosis has crucial consequences for the treatment and for the patient. In case of a misdiagnosed periprosthetic infection, revision of the prosthesis without appropriate debridement would keep a failed total hip replacement and risk an early failure. On the other hand a wrong assumption about periprosthetic infection caused by a false positive test, the patient has to undergo surgery which would be highly inadequate as a girdle stone operation or a cemented revision .

The diagnosis of PJI is based on the clinical findings of arthritis, an abnormal synovial fluid (SF) analysis, and microbiologic confirmation with a positive SF gram stain or culture There are limitations to cultures which may include the following: a delay of at least 2 days from the time of submission for the recovery of the pathogen on the culture medium, the results can be affected by a small inoculum, fastidious organisms may require specialized microbiologic testing, and prior antibiotics may render the culture negative Thus, there is a need for a rapid, sensitive, and specific method in the diagnosis of PJI.

The synovial fluid alpha-defensin test is an immunoassay that was specifically developed to aid in the diagnosis of prosthetic joint infection PJI .

The simplicity of the alpha-defensin test, combined with its ability to provide a clinical result soon after a preoperative joint aspiration, makes it an attractive tool for diagnosing PJI The alpha-defensin protein is an antimicrobial peptide that is naturally released by neutrophils responding to a pathogen in the synovial fluid. It is therefore very reasonable to question whether this antimicrobial peptide is released in response to all pathogens and also whether the alpha-defensin test can detect PJIs caused by all organisms .

The sensitivity and the specificity of the alpha-defensin immunoassay test have been reported to be above 96% .

Use of broad-range 16S rRNA gene PCR as a tool for identification of bacteria is possible because the 16S rRNA gene is present in all bacteria. The 16S rRNA gene consists of highly conserved nucleotide sequences, interspersed with variable regions that are genus- or species-specific.

Molecular diagnostic tests using polymerase chain reaction (PCR) are emerging as a tool for the diagnosis of infections and noninfectious conditions. The application of PCR techniques with primers derived from the highly conserved regions of the bacterial 16S rRNA gene has been useful in the detection of bacterial organisms.

Being tested
Alpha defensin and 16SrRNA gene
Keywords
Alpha defensin, 16S rRNA gene

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Alpha defensin and 16SrRNA geneDiagnostic test

    Also called CBC, CRP, ESR, Culture and antibiotic sensitivity of synovial fluid

    Alpha defensin 16S rRNA gene CBC: Complete blood count CRP: C reactive protein ESR: Erythrocyte sedimentation rate Culture and antibiotic sensitivity of synovial fluid

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Diagnostic value of Alpha defensin in diagnosis of Prosthetic joint infection

    value of measuring Alpha defensin by enzyme linked immunosorbent assay (ELISA) in diagnosis of Prosthetic joint infection as a rapid bio marker

    Measured: 2 days

  2. Diagnostic value of 16S rRNA gene in diagnosis of Prosthetic joint infection

    value of measuring 16S rRNA gene by conventional PCR in diagnosis of Prosthetic joint infection as more accurate test

    Measured: 2 days

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Oct 2018
  2. Study start1 Jan 2019 (estimated)
  3. Primary completion1 Jan 2020 (estimated)
  4. Study completion1 Jan 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Prospective
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03714165
Sponsor's protocol ID
Diagnosis of PJI
Status last verified
Oct 2018
First submitted
18 Oct 2018
Last updated
22 Oct 2018
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Slullitel PA, Onativia JI, Buttaro MA, Sanchez ML, Comba F, Zanotti G, Piccaluga F. State-of-the-art diagnosis and surgical treatment of acute peri-prosthetic joint infection following primary total hip arthroplasty. EFORT Open Rev. 2018 Jul 17;3(7):434-441. doi: 10.1302/2058-5241.3.170032. eCollection 2018 Jul.

    PubMed 30233819
  • Dudareva M, Barrett L, Figtree M, Scarborough M, Watanabe M, Newnham R, Wallis R, Oakley S, Kendrick B, Stubbs D, McNally MA, Bejon P, Atkins BA, Taylor A, Brent AJ. Sonication versus Tissue Sampling for Diagnosis of Prosthetic Joint and Other Orthopedic Device-Related Infections. J Clin Microbiol. 2018 Nov 27;56(12):e00688-18. doi: 10.1128/JCM.00688-18. Print 2018 Dec.

    PubMed 30209185

Questions about this trial

What is this clinical trial studying?

An observational study of Prosthetic Joint Infection, run by Assiut University at 1 site in Egypt.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 22 Oct 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ayat Bakhet Mostafa, Dr (01003880813, ayabakhet87@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Diagnostic value of Alpha defensin in diagnosis of Prosthetic joint infection (time frame: 2 days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03714165, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in